SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.
Stepwise modification of a conformationally stabilised analogue of the fragment of somatostatin which had been thought to be essential biologically active moiety has enabled us to synthesise the analogue H-(D) Phe-Cys-Phe-(D) Trp-Lys-Thr-Cys-Thr(ol) code-named SMS 201-995, which in vitro is three times more potent than the native hormone in inhibiting the secretion of growth hormone, which is highly resistant to degradation by pure enzymes and by tissue homogenates, which in vivo in rat and rhesus monkey is (depending on test system) at least 20 times more active than somatostatin, which is much longer acting, and which moreover in both species is much more selective in inhibiting the secretion of growth hormone than that of insulin. The compound is active by several routes of administration including the oral, is well tolerated both in laboratory animals and in man, and is currently undergoing preliminary clinical trial.
D000818:Animals; D002478:Cells, Cultured; D004341:Drug Evaluation; D005260:Female; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D008253:Macaca mulatta / Q000502:physiology; D008297:Male; D015282:Octreotide; D010902:Pituitary Gland / Q000378:metabolism; D011863:Radioimmunoassay; D051381:Rats; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000494:pharmacology
D013004:Somatostatin; D013006:Growth Hormone; D015282:Octreotide